

PRESS RELEASE

08 May 2024 18:11:00 CEST

## **ANNUAL GENERAL MEETING OF INFANT BACTERIAL THERAPEUTICS**

**At the Annual General Meeting of Infant Bacterial Therapeutics AB (publ) on May 8, 2024, among other things, the following was resolved:**

- to adopt the income statement and balance sheet and the consolidated income statement and consolidated balance sheet;
- that no dividend is made;
- discharge from liability granted to Board members and the managing director,
- that the Board shall consist of five members without deputies;
- that remuneration shall be paid to the Chairman of the Board of SEK 340,000 and an unchanged additional remuneration for the work as Chairman of the Board of SEK 400,000 and to other Board members not employed by the company of SEK 170,000 each;
- that remuneration shall be paid to the members of the Remuneration Committee of SEK 44,000 to the Chairman and SEK 22,000 to each of the other members of the Remuneration Committee;
- that remuneration shall be paid to the members of the newly established Audit Committee of SEK 50,000 to the Chairman and SEK 25,000 to the other members of the Audit Committee;
- that the audit fee be paid according to approved invoice;
- re-election of Margareta Hagman, Eva Idén, Anthon Jahreskog, Kristina Sjöblom Nygren and Peter Rothschild as Board members;
- re-election of Peter Rothschild as Chairman of the Board;
- re-election of the registered accounting firm Deloitte AB;
- on appointment of the Nominating Committee in accordance with the Nominating Committee's proposal;
- approval of the Board's remuneration report;
- authorization for a new issuance of shares in accordance with the Board's proposal; and
- implementation of an incentive program for the company's employees and key persons engaged as consultants through the issuance of a maximum of 165,000 warrants in accordance with the Board's proposal. The warrants shall entitle to subscription for a maximum of 165,000 B-shares in the company during the period June 1, 2027 up to and including September 30, 2027 at a subscription price corresponding to 200 percent of the volume-weighted average price of the company's share according to Nasdaq Stockholm's official price list during ten trading days before May 8, 2024.

---

## **Contacts**

Staffan Strömberg, CEO

Maria Ekdahl, CFO

[info@ibtherapeutics.com](mailto:info@ibtherapeutics.com)

+46 76 219 37 38

---

## **About Us**

**Infant Bacterial Therapeutics AB ("IBT") is a public company domiciled in Stockholm. The company's Class B shares are since September 10, 2018, listed on Nasdaq Stockholm (IBTB).**

IBT is a pharmaceutical company whose purpose is to develop and commercialize drugs for diseases affecting premature babies. During the 12 years of drug development IBT has gained unique expertise in the field of drugs using live bacteria as active substances, this is a key competitive factor for our development programs.

IBT's main focus is the drug candidate IBP-9414, a formulated bacterial strain naturally found in human breast milk. The development program is designed to show a reduced incidence of necrotizing enterocolitis ("NEC") and improved gastrointestinal function ("SFT"). IBP-9414, is expected to be the first product in the new class of biologics called "Live Biotherapeutic Products" for premature infants. Upon approval, it would be the first product to prevent NEC and improve Sustained Feeding Tolerance ("SFT") in newborns. The drug development of IBP-9414 is currently in its final stages and IBT expects to receive regulatory approval in 2025 for this important product for premature babies.

The portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP-1016, for the treatment of gastroschisis, a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs. IBP-1118 to prevent retinopathy of prematurity (ROP), one of the leading causes of blindness in premature babies, and IBP-1122 to eliminate vancomycin-resistant enterococci (VRE), which cause antibiotic-resistant hospital infections.

Through the development of these drugs, IBT can address medical needs where no sufficient treatments are available.

---

## **Attachments**

[Annual General Meeting of Infant Bacterial Therapeutics](#)